Bitfarms Technologies, Vestis, and More Stocks See Action From Activist Investors -- Barrons.com

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen

Barron'sJun 28 20:11 ET

Disc Medicine Insider Bought Shares Worth $3,000,024, According to a Recent SEC Filing

Mona Ashiya, Director, on June 17, 2024, executed a purchase for 83,334 shares in Disc Medicine (IRON) for $3,000,024. Following the Form 4 filing with the SEC, Ashiya has control over a total of 235,

MT NewswiresJun 20 17:32 ET

Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $79

Stifel analyst Benjamin Burnett maintains $Disc Medicine(IRON.US)$ with a buy rating, and adjusts the target price from $72 to $79.According to TipRanks data, the analyst has a success rate of 35.3% a

moomoo NewsJun 17 22:32 ET · Ratings

BMO Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Cuts Target Price to $50

BMO Capital analyst Evan Seigerman maintains $Disc Medicine(IRON.US)$ with a buy rating, and adjusts the target price from $70 to $50.According to TipRanks data, the analyst has a success rate of 0.0%

moomoo NewsJun 17 14:31 ET · Ratings

BMO Capital Reiterates Outperform on Disc Medicine, Raises Price Target to $70

BMO Capital analyst Evan Seigerman reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $50 to $70.

BenzingaJun 17 09:15 ET

Express News | Disc Medicine Inc : Wedbush Raises Target Price to $57 From $43

ReutersJun 17 00:55 ET